Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stadlbauer, V; Horvath, A; Ribitsch, W; Schmerböck, B; Schilcher, G; Lemesch, S; Stiegler, P; Rosenkranz, AR; Fickert, P; Leber, B.
Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis.
Sci Rep. 2017; 7(1):15601-15601
Doi: 10.1038/s41598-017-15650-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Horvath Angela
- Stadlbauer-Köllner Vanessa
- Co-Autor*innen der Med Uni Graz
- Fickert Peter
- Leber Bettina
- Lemesch Sandra
- Ribitsch Werner
- Rosenkranz Alexander
- Schilcher Gernot
- Stiegler Philipp
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Complications of end-stage renal disease (ESRD) are critically related to inflammation. The gut microbiome is a key driver of inflammation. Since dialysis modalities may differently influence the gut microbiome, we aimed to compare the effects of haemodialysis (HD) and peritoneal dialysis (PD) on patients' gut microbiome composition and function. We therefore studied faecal microbiome composition and function as well as inflammation and gut permeability in 30 patients with ESRD (15 HD, 15 PD) and compared to 21 healthy controls. We found an increase in potentially pathogenic species and a decrease in beneficial species in patients on HD and to a lesser extend in patients on PD when compared to controls. These changes in taxonomic composition also resulted in differences in predicted metagenome functions of the faecal microbiome. In HD but not in PD, changes in microbiome composition were associated with an increase in c-reactive protein (CRP) but not with intestinal inflammation or gut permeability. In conclusion microbiome composition in ESRD differs from healthy controls but also between modes of dialysis. These differences are associated with systemic inflammation and cannot completely be explained by dialysis vintage. The mode of renal replacement therapy seems to be an important driver of dysbiosis in ESRD.